Semaglyn/ Mashema / Alterme
by Zydus Lifesciences · DCGI approved March 2026
| Active ingredient | Semaglutide (GLP-1 receptor agonist) |
| Indication | Type 2 Diabetes + Obesity |
| Manufacturer | Zydus Lifesciences Ltd |
| DCGI status | Approved March 2026 |
| Price (MRP) | ₹2,200–5,500/month Lower range for T2D dosing, higher for obesity-dose maintenance |
| Format | Reusable multi-dose pen 15 mg / 3 mL cartridge — replace cartridges, not the device |
| Prescription | Schedule H — required |
How Semaglyn compares
Semaglyn is the only reusable-pen semaglutide on the Indian market. Patients keep the same device through dose-titration, replacing only cartridges — a meaningful cost and convenience advantage during the standard 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg/week escalation. Mashema and Alterme are sister brand names for the same product, used for distinct distribution channels.
About Zydus Lifesciences
Zydus Lifesciences holds the largest licensing footprint among Indian semaglutide generics, with co-marketing agreements covering Lupin (Semanext, Livarise) and Torrent (Sembolic, Semalix). Effectively, Zydus is the manufacturing platform for several of the leading Indian generic brands.
Manufacturer announcement
Additional source
Business Standard — Zydus semaglutide launchGLP-1 Check is informational, not a medical diagnosis. Semaglutide is a Schedule H drug in India and requires a prescription from a registered medical practitioner. Always consult a qualified physician before starting any treatment.